Neurocrine Biosciences Inc (NBIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurocrine Biosciences Inc (NBIX) has a cash flow conversion efficiency ratio of 0.119x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($388.40 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neurocrine Biosciences Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Neurocrine Biosciences Inc for a breakdown of total debt and financial obligations.
Neurocrine Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurocrine Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SOUTH32 Ltd
AU:S32
|
0.060x |
|
CNH Industrial N.V.
NYSE:CNH
|
0.084x |
|
Coloplast A/S
CO:COLO-B
|
0.162x |
|
First Financial Holding Co Ltd
TW:2892
|
-0.010x |
|
NESTE OYJ UNSP.ADR 1/2
F:NEFA
|
N/A |
|
CNA Financial Corporation
NYSE:CNA
|
0.064x |
|
TCL Corp
SHE:000100
|
0.054x |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
0.167x |
Annual Cash Flow Conversion Efficiency for Neurocrine Biosciences Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Neurocrine Biosciences Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Neurocrine Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.25 Billion | $782.70 Million | 0.241x | +4.65% |
| 2024-12-31 | $2.59 Billion | $595.40 Million | 0.230x | +31.61% |
| 2023-12-31 | $2.23 Billion | $389.90 Million | 0.175x | -12.10% |
| 2022-12-31 | $1.71 Billion | $339.40 Million | 0.199x | +6.46% |
| 2021-12-31 | $1.37 Billion | $256.50 Million | 0.187x | -7.99% |
| 2020-12-31 | $1.13 Billion | $228.50 Million | 0.203x | -12.09% |
| 2019-12-31 | $636.90 Million | $147.00 Million | 0.231x | +9.43% |
| 2018-12-31 | $480.76 Million | $101.40 Million | 0.211x | +183.21% |
| 2017-12-31 | $372.14 Million | $-94.33 Million | -0.253x | +24.83% |
| 2016-12-31 | $314.88 Million | $-106.18 Million | -0.337x | -276.69% |
| 2015-12-31 | $424.45 Million | $-38.00 Million | -0.090x | +60.37% |
| 2014-12-31 | $208.70 Million | $-47.14 Million | -0.226x | +8.14% |
| 2013-12-31 | $120.41 Million | $-29.61 Million | -0.246x | -7.55% |
| 2012-12-31 | $154.37 Million | $-35.29 Million | -0.229x | -1867.95% |
| 2011-12-31 | $60.08 Million | $-698.00K | -0.012x | -100.45% |
| 2010-12-31 | $19.34 Million | $49.94 Million | 2.582x | +119.23% |
| 2009-12-31 | $3.95 Million | $-53.09 Million | -13.428x | -565.82% |
| 2008-12-31 | $36.77 Million | $-74.17 Million | -2.017x | -303.45% |
| 2007-12-31 | $118.70 Million | $-59.33 Million | -0.500x | -58.37% |
| 2006-12-31 | $314.72 Million | $-99.33 Million | -0.316x | -299.85% |
| 2005-12-31 | $390.10 Million | $-30.79 Million | -0.079x | +68.91% |
| 2004-12-31 | $393.83 Million | $-99.99 Million | -0.254x | -367.46% |
| 2003-12-31 | $391.12 Million | $37.13 Million | 0.095x | +126.82% |
| 2002-12-31 | $224.25 Million | $-79.36 Million | -0.354x | -402.61% |
| 2001-12-31 | $310.39 Million | $-21.86 Million | -0.070x | +38.36% |
| 2000-12-31 | $163.21 Million | $-18.64 Million | -0.114x | -6.92% |
| 1999-12-31 | $96.40 Million | $-10.30 Million | -0.107x | +28.10% |
| 1998-12-31 | $72.00 Million | $-10.70 Million | -0.149x | -212.40% |
| 1997-12-31 | $83.20 Million | $11.00 Million | 0.132x | +43.66% |
| 1996-12-31 | $72.80 Million | $6.70 Million | 0.092x | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more